Earnings Summary

Eagle Pharmaceuticals Inc.’s revenue fell -12.8% since last year same period to $64.65Mn in the Q2 2023. On a quarterly growth basis, Eagle Pharmaceuticals Inc. has generated -2.5% fall in its revenue since last 3-months.

Eagle Pharmaceuticals Inc.’s net profit jumped 154.65% since last year same period to $5.16Mn in the Q2 2023. On a quarterly growth basis, Eagle Pharmaceuticals Inc. has generated -10.19% fall in its net profits since last 3-months.

Eagle Pharmaceuticals Inc.’s net profit margin jumped 162.67% since last year same period to 7.99% in the Q2 2023. On a quarterly growth basis, Eagle Pharmaceuticals Inc. has generated -7.89% fall in its net profit margins since last 3-months.

Eagle Pharmaceuticals Inc.’s price-to-earnings ratio after this Q2 2023 earnings stands at 5.42.

Eagle Pharmaceuticals Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.98 - a -2.97% fall from last quarter’s estimates.

Eagle Pharmaceuticals Inc.’s earning per share (EPS) estimates for the current year stand at 0.98.

Eagle Pharmaceuticals Inc.’s earning per share (EPS) fell -2.68% since last year same period to 1.09 in the Q3 2023. This indicates that the Eagle Pharmaceuticals Inc. has generated -2.68% annual rate of fall in its earning per share (EPS) in the last 4 quarters.